EW (Edwards Lifesciences) Tax Provision: $-225 Mil (TTM As of Mar. 2026)


EW Edwards Lifesciences Corp EW
97 GF Score
Price $95.18
GF Value $93.48
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Edwards Lifesciences Tax Provision?

Edwards Lifesciences EW +0.86% 97 Tax Provision is $-225 Mil as of Mar. 2026. GuruFocus rates EW with a GF Score™ of 97/100 and a GF Value™ of $93.48 (Fairly Valued). The stock has 5 warning signs investors should review.

Edwards Lifesciences's tax provision for the three months ended in Mar. 2026 was $-78 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2026 was $-225 Mil.

Edwards Lifesciences Tax Provision Historical Data

* Premium members only.

The historical data trend for Edwards Lifesciences's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edwards Lifesciences Tax Provision Chart

Edwards Lifesciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Provision
Get a 7-Day Free Trial Premium Member Only Premium Member Only -198.90 -195.50 -152.40 -152.10 -216.90

Edwards Lifesciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -70.30 -64.30 -56.10 -26.20 -78.30
EW
97GF Score
Edwards Lifesciences Corp EW
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Edwards Lifesciences Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-225 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of $-225 Mil mean?
Edwards Lifesciences (EW) has a Tax Provision of $-225 Mil as of Mar. 2026. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Edwards Lifesciences and its competitors.
Is Edwards Lifesciences' Tax Provision too high?
Edwards Lifesciences' current Tax Provision is $-225 Mil. Overall, Edwards Lifesciences has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' Tax Provision compare to BSX and GEHC?
Edwards Lifesciences' Tax Provision of $-225 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Medical Devices & Instruments company?
A good Tax Provision depends on the Medical Devices & Instruments industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Edwards Lifesciences and its competitors. Edwards Lifesciences's current Tax Provision is $-225 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Edwards Lifesciences (EW) is currently considered Fairly Valued. The stock's GF Value™ is $93.48, compared to a current price of $95.18 — trading 1.8% above its estimated fair value. The current Tax Provision is $-225 Mil. Edwards Lifesciences' overall GF Score™ is 97/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For Edwards Lifesciences (EW), the current Tax Provision is $-225 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Edwards Lifesciences (EW) Overvalued in 2026?

Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be overvalued. The current stock price of $95.18 is trading 1.8% above its estimated GF Value™ of $93.48. GuruFocus considers Edwards Lifesciences to be Fairly Valued.

Key valuation signals for EW:

  • Tax Provision: $-225 Mil
  • GF Value™: $93.48 vs. price of $95.18 (1.8% above fair value)
  • GF Score™: 97/100 with 5 warning signs

No single metric tells the full story. See the EW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Edwards Lifesciences Business Description

Address One Edwards Way, Irvine, CA, USA, 92614
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
97GF Score

Get the complete analysis for EW

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$95.18
Price
$93.48
GF Value